• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

急性和慢性口服给药后人体内纳曲酮的系统可用性及其他药代动力学参数的评估。

Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration.

作者信息

Kogan M J, Verebey K, Mule S J

出版信息

Res Commun Chem Pathol Pharmacol. 1977 Sep;18(1):29-34.

PMID:905632
Abstract

First pass metabolism, metabolic clearance, volume of distribution and steady state plasma levels were estimated in man following acute and chronic 100 mg oral doses of naltrexone. Essentially no statistical differences was observed in these values between the acute and chronic physiologic state. The values for the first pass effect were 79.6 +/- 4.6% and 78.0 +/- 3.0% for acute and chronic treatment respectively. From our pharmacokinetic data an apparent chronic release rate (ACRR) for a sustained release preparation of naltrexone was calculated as 11.8 microgram/kg/hr. In practice a release rate of one half the ACRR should be sufficient to provide continuous antagonism of 25 mg i.v. heroin. In conclusion our data clearly indicate that naltrexone is an effective and safe narcotic antagonist in man.

摘要

在给予人体100毫克口服剂量的纳曲酮进行急性和慢性给药后,评估了首过代谢、代谢清除率、分布容积和稳态血浆水平。在急性和慢性生理状态下,这些值基本未观察到统计学差异。急性和慢性治疗的首过效应值分别为79.6±4.6%和78.0±3.0%。根据我们的药代动力学数据,计算出纳曲酮缓释制剂的表观慢性释放率(ACRR)为11.8微克/千克/小时。在实际应用中,ACRR的一半释放率应足以对25毫克静脉注射海洛因提供持续拮抗作用。总之,我们的数据清楚地表明,纳曲酮在人体中是一种有效且安全的麻醉拮抗剂。

相似文献

1
Estimation of the systemic availability and other pharmacokinetic parameters of naltrexone in man after acute and chronic oral administration.急性和慢性口服给药后人体内纳曲酮的系统可用性及其他药代动力学参数的评估。
Res Commun Chem Pathol Pharmacol. 1977 Sep;18(1):29-34.
2
Naltrexone disposition in man after subcutaneous administration.皮下注射后纳曲酮在人体内的处置情况。
Drug Metab Dispos. 1984 Nov-Dec;12(6):677-82.
3
Bioequivalence, dose-proportionality, and pharmacokinetics of naltrexone after oral administration.口服纳曲酮后的生物等效性、剂量比例性及药代动力学
J Clin Psychiatry. 1984 Sep;45(9 Pt 2):15-9.
4
The clinical pharmacology of naltrexone: pharmacology and pharmacodynamics.
NIDA Res Monogr. 1981;28:147-58.
5
Metabolism and disposition of naltrexone in man after oral and intravenous administration.
Drug Metab Dispos. 1981 Jul-Aug;9(4):369-75.
6
Naltrexone: disposition, metabolism, and effects after acute and chronic dosing.
Clin Pharmacol Ther. 1976 Sep;20(3):315-28. doi: 10.1002/cpt1976203315.
7
Pharmacokinetics of naloxone and naltrexone in the dog.
J Pharmacol Exp Ther. 1979 Feb;208(2):254-6.
8
Pharmacokinetics and pharmacodynamics of subcutaneous naltrexone pellets in the rat.皮下注射纳曲酮微丸在大鼠体内的药代动力学和药效学
J Pharmacol Exp Ther. 1986 Apr;237(1):126-30.
9
Testing of drug delivery systems for use in the treatment of narcotic addiction.用于治疗麻醉品成瘾的药物递送系统的测试。
Natl Inst Drug Abuse Res Monogr Ser. 1975(4):43-5.
10
Pharmacokinetic quantitation of naltrexone release from several sustained-release delivery systems.几种缓释给药系统中纳曲酮释放的药代动力学定量分析。
NIDA Res Monogr. 1981;28:172-84.

引用本文的文献

1
Neuroendocrine effects of naltrexone versus nalmefene in humans.纳曲酮与纳美芬对人类的神经内分泌影响。
Hum Psychopharmacol. 2020 Mar;35(2):e2726. doi: 10.1002/hup.2726. Epub 2020 Feb 12.
2
Cholestasis and endogenous opioids: liver disease and exogenous opioid pharmacokinetics.胆汁淤积与内源性阿片类物质:肝脏疾病与外源性阿片类药物的药代动力学
Clin Pharmacokinet. 2007;46(10):825-50. doi: 10.2165/00003088-200746100-00002.
3
Naltrexone reduces the relative reinforcing value of nicotine in a cigarette smoking choice paradigm.纳曲酮在吸烟选择范式中降低了尼古丁的相对强化值。
Psychopharmacology (Berl). 2005 Jun;180(1):41-8. doi: 10.1007/s00213-004-2136-8. Epub 2005 Jan 29.
4
Bioavailability prediction based on molecular structure for a diverse series of drugs.基于分子结构对多种药物进行生物利用度预测。
Pharm Res. 2004 Jan;21(1):68-82. doi: 10.1023/b:pham.0000012154.09631.26.
5
Pharmacokinetic and pharmacodynamic principles of illicit drug use and treatment of illicit drug users.非法药物使用的药代动力学和药效学原理以及非法药物使用者的治疗
Clin Pharmacokinet. 1997 Nov;33(5):344-400. doi: 10.2165/00003088-199733050-00003.
6
Clinical pharmacokinetics of narcotic agonist-antagonist drugs.麻醉性激动剂-拮抗剂药物的临床药代动力学。
Clin Pharmacokinet. 1983 Jul-Aug;8(4):332-43. doi: 10.2165/00003088-198308040-00004.
7
Naltrexone-3-salicylate (a prodrug of naltrexone): synthesis and pharmacokinetics in dogs.纳曲酮-3-水杨酸盐(纳曲酮的一种前药):在犬类中的合成与药代动力学
Pharm Res. 1988 Feb;5(2):113-5. doi: 10.1023/a:1015944302567.
8
Naltrexone. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of opioid dependence.纳曲酮。对其药效学和药代动力学特性以及在阿片类药物依赖管理中的治疗效果的综述。
Drugs. 1988 Mar;35(3):192-213. doi: 10.2165/00003495-198835030-00002.